Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Hepatic Medicine: Evidence and Research
- Vol. 12, 61-68
Abstract
Purpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study. Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12). Results: One hundred and nineteen Russian participants were randomized (immediate-treatment group, n=88; deferred-treatment group, n=31). Most participants were white (99%) with HCV genotype 1b infection (97%) and mild-to-moderate (F0-F2) fibrosis (70%). SVR12 was achieved by 98.9% participants in the immediate-treatment group and by 100% of those receiving deferred elbasvir/grazoprevir in the deferred-treatment group. One participant relapsed with nonstructural protein 5A (NS5A) L28M and Y93H resistance-associated substitutions at baseline and at time of failure. Drug-related adverse events were reported by 19% of participants receiving elbasvir/grazoprevir in the immediate-treatment group and by 16% of those receiving placebo in the deferred-treatment group. No serious adverse event or deaths occurred, and no participant discontinued treatment owing to an adverse event. Conclusion: Elbasvir/grazoprevir for 12 weeks was highly effective in treatment-naive Russian individuals with HCV genotype 1b infection.Keywords
This publication has 23 references indexed in Scilit:
- Hepatitis C in the Russian Federation: challenges and future directionsHepatic Medicine: Evidence and Research, 2016
- Efficacy of Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Genotype-1 and -3 HCV Infection: Results from a Russian Phase IIIb StudyAntiviral Therapy, 2015
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyThe Lancet, 2015
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialThe Lancet HIV, 2015
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 InfectionAnnals of Internal Medicine, 2015
- Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype ActivityChemMedChem, 2013
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant VariantsAntimicrobial Agents and Chemotherapy, 2012
- Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorACS Medicinal Chemistry Letters, 2012
- Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan).1997
- Prevalence of hepatitis C virus and distribution of its genotypes in Northern EurasiaArchives of Virology, 1996